/
Asthma and COPD Asthma and COPD

Asthma and COPD - PowerPoint Presentation

debby-jeon
debby-jeon . @debby-jeon
Follow
417 views
Uploaded On 2017-07-10

Asthma and COPD - PPT Presentation

Lauren Clark Outline Introduction Definition Epidemiology Etiology Cost amp Burden Intervention Research Introduction Chronic Lower Respiratory Diseases Chronic lower respiratory diseases ID: 568698

copd asthma risk prevention asthma copd prevention risk health people chronic disease public factors diagnosis years goal genetic related primary 000 smoking

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Asthma and COPD" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Asthma and COPD

Lauren Clark Slide2

Outline

Introduction

Definition

Epidemiology

Etiology

Cost & Burden

Intervention

ResearchSlide3

IntroductionSlide4

Chronic Lower Respiratory Diseases

Chronic lower respiratory diseases

:

Asthma, bronchitis, COPD, emphysema, cystic fibrosis, bronchiectasis, pneumoconiosis, sleep apnea

“The ‘upstream’ causes and ‘downstream’ consequences of chronic respiratory disease are complex, and related to the specific type of disease”.Slide5

Definitions

COPD

Progressive

non-reversible

airway obstruction

Bronchitis – Excessive tracheobronchial mucus associated with bronchial airway narrowing and cough

Emphysema – Alveolar destruction and airspace enlargement

Asthma

Reversible

airway obstruction

Airway inflammation and reactive airway Slide6
Slide7

COPD

Chronic Obstructive Pulmonary Disease

a common

preventable

but

irreversible

disease, characterized by persistent airflow limitation that is usually

progressive

and associated with an enhanced chronic inflammatory response in the airways and the lung to particles or gases

The chronic airflow limitation characteristic of COPD is caused by a mixture of small airways disease (

chronic bronchitis) and parenchymal destruction (

emphysema), the relative contributions of which vary from person to person Airflow limitations, cough, other respiratory symptomsSlide8
Slide9

How to diagnose

COPDSlide10

Asthma

chronic disease involving the inflammation of airways in the lungs

Airways become more inflamed and muscles tighten trigging systems

Coughing, wheezing, shortness of breather and/or chest tightness

In most cases, we don’t know the exact causes of asthma and we don’t know how to cure it

No cure but can be adequately treated

Types:

Exercise-induced

Allergic asthma

Occupational asthma

Childhood asthmaSlide11
Slide12

How to Diagnose

Asthma

Obstructive lung disease (COPD & Asthma) is the

inability to exhale all the air in the lun

g resulting in

dyspnea.

Diagnosis

:

Spirometry

Forced expiratory volume in the first one sec (FEV1)/Forced vital capacity (FVC)

Obstructive FEV1/FVC < 0.75Slide13

EpidemiologySlide14

COPD

Prevalence

In the National Health and Nutrition Examination Survey, 5% men and 6% of women report physician diagnosed COPD. Rates as high as 9-13 % have been estimated in some populations

Approximately

15 million adults

have been diagnosed with COPD in all 50 States

Since nearly 24 million adults show signs of impaired lung function, researchers believe that COPD remains under-diagnosedSlide15
Slide16
Slide17
Slide18

Asthma

Prevalence

Affects 25.7 Million people nationally

Number of adults who currently have asthma: 17.7 million

Percent of adults who currently have asthma: 7.4%

Number of children who currently have asthma: 6.3 million

Percent of children who currently have asthma: 8.6%

Asthma prevalence in the United States,

2001–2010Slide19
Slide20

IA

ME

AK

WA

OR

CA

NV

ID

UT

MT

WY

CO

AZ

NM

TX

SD

NE

KS

OK

AR

LA

MN

WI

MI

IL

MO

IN

OH

KY

TN

MS

AL

GA

SC

FL

NC

VA

WV

PA

NY

MA

ND

VT

NH

DC

MD

DE

NJ

CT

RI

HI

PR

8.6 – 9.3

6.0 – 7.7

7.8 – 8.5

9.4 – 9.9

10.0 – 11.1

Adult Self-Reported Current Asthma Prevalence (%) by

State or Territory, 2010Slide21
Slide22
Slide23
Slide24

COPD

Incidence

Incidence has increased over the last 20 years, however has been a slight decrease in last 10 years

Greater among men than women

Greater in older individuals (>75)

Hard to determine actual percentages due very few studies measuring its incidence have been conductedSlide25

Asthma

Incidence

Incidence (2006-2008, ACBS)

3.8/1000 (0.38%) for adults

12.5/1000 (1.25% for childrenSlide26
Slide27

COPD

Etiology

COPD results from a gene-environment interaction.

Among people with the same smoking history, not all will develop COPD due to differences in

genetic predisposition

to the disease, or in how long they live

The genetic risk factor that is best documented is a

severe hereditary deficiency of alpha-1 antitrypsin

, a major circulating inhibitor of serine proteases

People with this deficiency have received two abnormal alpha-1 antitrypsin genes. One of these abnormal genes came from their mother and one from their father

The World Health Organization recommends that COPD patients from areas with a particularly high prevalence of alpha-1 antitrypsin deficiency should be screened for this genetic disorder. Slide28

COPD

Risk Factors

Exposure to particles

cigarette smoking is the most commonly encountered risk factor for COPD

Tobacco smoking (cigarette,

pipe, cigar, and other types of tobacco)

Indoor air pollution (such as biomass fuel used for cooking and heating & second hand smoke)

Outdoor air pollution

Occupational dusts and chemicals (irritants and fumes)

Age - COPD develops slowly over years, so most people are at least 35 to 40 years old when symptoms beginGenetics –

as noted before alpha-1-antitrypsin deficiency Any factor that affects lung growth during gestation and childhood has the potential for increasing an individual’s risk of developing COPD. Risk factors for COPD may also be related in more complex ways.

For example,

gender

may influence whether a person takes up smoking or experiences certain occupational or environmental exposures;

socioeconomic status

may be linked to a child’s birth weight (as it impacts on lung growth/development and in turn on susceptibility to develop the disease). Slide29

Asthma

Etiology

Allergic/ atopic/extrinsic

More common in children

Nonallergic

/

nonatropic

/intrinsic

More common in adults

Observation of higher IgE levels in patients of all age groups has added weight to the proposal of a unifying

hypothesisfor a both types of asthma Slide30

Asthma

Etiology

“Hygiene Hypothesis:

Increase in eczema, asthma, allergies

Family Size Study: as family size declined, allergies increased

Farm Study: Children growing up on farms has less allergies

Immunology studies are now supporting this theory

Potential outliers to this theory: Japan (lower asthma rates), Barbados (higher asthma rates).

More TV Watching

Decreased sighing, less activitySlide31

Asthma

Etiology

Genetic Component

If one parent has asthma, chances are 1 in 3 that each child will have asthma

If both parents have asthma, chances are 7 in 10 that each child will have asthma

Twin studies

Also

concludeconsiderable

genetic component of asthma, in which the genetic effects are mainly additive

However, identification of all asthma related genes is cincompleteSlide32

Asthma

Risk Factors

Having a blood relative (such as a parent or sibling) with asthma

Having another allergic condition, such as atopic dermatitis or allergic rhinitis (hay fever)

Being overweight

Being a smoker

Exposure to secondhand smoke

Exposure to exhaust fumes or other types of pollution

Exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturingSlide33

Asthma

Risk FactorsSlide34

COPD

MortalitySlide35

COPD

Mortality

COPD is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing

5

th

in 2002 projected to rise to 30% and be 3

rd

by 2030

COPD is the third leading cause of death in the United States behind cancer and heart disease

47.2 deaths per 100,000 populationIn 2009, 133,965 people died of COPD of which more than half (52.3%) were in womenCOPD has an age-adjusted death rate of 41.2 per 100,000 population; meaning that 41 persons out of 100,000 people died from COPD in 2009Slide36
Slide37

COPD

Global Mortality Slide38

Asthma

Mortality

Deaths due to asthma are uncommon but are of serious concern because many of them are preventable

contributing to less than 1% of all deaths in most countries worldwide

1.1 deaths per 100,000 population in the US

Most deaths occur in older adults after middle age

Over the past 50 years, mortality rates in these younger age groups have fluctuated markedly in several high-income countries, attributed to changes in medical care for asthma, especially the introduction of new asthma medicationsSlide39
Slide40
Slide41
Slide42

Cost & BurdenSlide43

Cost of

COPD

Direct medical costs for COPD in the US are more than

$32 billion each year

Indirect costs

$20.4 billion.

The yearly financial toll of COPD is expected to reach an estimated

$49 billion by 2020.

An estimated 715,000 hospital discharges were reported in 2010; a discharge rate of 23.2 per 100,000 population

COPD is an important cause of hospitalization in our aged population Average length of stay with chronic bronchitis as first-listed diagnosis: 4.5 days285,000 visits to emergency departments with chronic and unspecified bronchitis as the primary hospital discharge diagnosis

10.8% of residents in assisted living or other residential care have COPDSlide44
Slide45

Cost of

Asthma

Direct medical costs for Asthma in the US are more than

$50.1 billion each year

Indirect costs

$5.9 billion

Number of visits to physician offices with asthma as primary diagnosis: 10.5 million

Number of visits to emergency departments with asthma as primary diagnosis: 1.8 million

Number of discharges with asthma as first-listed diagnosis: 439,000

Average length of stay for asthma diagnosis: 3.6 daysSlide46
Slide47

Burden of

COPD

A Lung Association survey revealed that 51% of all COPD patients say their condition limits their ability to work.

It also limits them in normal physical exertion, household chores, social activities , sleeping and family activities.

Findings of a 8 year prospective study suggested that disability in COPD patients progresses gradually over 7.5 years after initial diagnosis. After 7.5 years, most COPD patients are no longer capable of productive work. Slide48

Burden of

Asthma

Slide49
Slide50

InterventionSlide51

COPD

Prevention

Approximately

75% of COPD cases are attributed to cigarette smoking.

Occupation-related exposures may account for another 15% of COPD cases

Genetic factors, asthma, respiratory infections, and indoor and outdoor exposures to air pollutants also play a role 10%

Public health programs and policies that focus on tobacco-use prevention and cessation, reducing occupational exposure to dusts and chemicals, and reducing other indoor and outdoor air pollutants are critically important

Early treatment and control of asthma may also prevent the development of COPD.Slide52

COPD

Primary PreventionSlide53

COPD

Secondary & Tertiary PreventionSlide54

Public Health Goals

Goal 1: Surveillance and Evaluation

Improve collection, analysis, dissemination, and reporting of COPD-related public health data.

Goal 2: Public Health Research and Prevention Strategies

Improve understanding of COPD development, prevention, and treatment.

Goal 3: Programs and Policies

Increase effective collaboration among stakeholders with COPD-related interests.

Goal 4: Communication

Heighten awareness of COPD in the following groups: people with COPD and their families, people with COPD risk factors, health professionals (especially primary care providers), provider systems, media, decision makers, policy makers, and the public. Slide55

COPD

Treatment Options

Treatment of COPD requires a careful and thorough evaluation by a physician to help alleviate symptoms, decrease the frequency and severity of exacerbations, and increase exercise tolerance. Slide56

Asthma

Prevention

Primary Prevention:

Increasing prevalence with unknown etiology.

Smoking cessation, exercise and healthy weight.

Breast feeding

Living with a dog (not at cat)

Secondary Prevention :

“While we don’t know why asthma rates are rising, we do know that people with asthma can control their symptoms by avoiding asthma triggers and correctly using prescribed medications, such as inhaled corticosteroids.” - CDC

Occupational Asthma. Aluminum, anhydride, alpha amylase, colophony, crab, detergent enzyme, enzyme, egg, insect, isocyanate, laboratory animal, latex, meat, platinum, shrimp, solder, and western red cedar. (Per CDC)

Avoidance of Triggers:Allergens, smoking, flu, RSV, etc.Slide57

Asthma

Prevention

Tertiary Prevention :

Education

Asthma Action Plan

Improved Medical Care

Routine Care

Access to MedicationsSlide58
Slide59

Public Health Goals

Goal 1: Surveillance and Evaluation

Improve collection, analysis, dissemination, and reporting of asthma-related public health data.

Goal 2: Public Health Research and Prevention Strategies

Improve understanding of asthma development, prevention, and treatment.

Goal 3: Programs and Policies

Increase effective collaboration among stakeholders with asthma-related interests.

Goal 4: Communication

Heighten awareness of asthma in the following groups: people with asthma and their families, people with asthma risk factors, families, health professionals (especially primary care providers), provider systems, media, decision makers, policy makers, and the public. Slide60

Current ResearchSlide61
Slide62
Slide63
Slide64
Slide65
Slide66
Slide67
Slide68

Research Gaps

What we still need to learn is how best to deliver healthcare that is better integrated and more coherent.

That is, care based on a strategic alliance between primary and secondary care and supported when needed by interdisciplinary teams for patients with high risk and complex COPD.

Much of the evidence concerning risk factors for COPD comes from cross-sectional epidemiological studies that identify associations rather than cause-and-effect relationships.

Although several longitudinal studies of COPD have followed groups and populations for up to 20 years 25, none has monitored the progression of the disease through its entire course, or has included the pre-and perinatal periods which may be important in shaping an individual’s future COPD risk.

Develop better epidemical data Slide69

Research Gaps

Further research into the genetic factors in asthma development

Develop understanding of asthma causationSlide70

Questions?